Restoring tumour-specific T cell immunity using directly inhibiting PD-L1-PD-1 signalling has shown sustained anticancer activity in the management of PD-L1-positive NSCLC (Borghaei et al. 2021; Horn et al. 2018; Ikeda et al. 2021). Here, PDCD1 is linked to non-small cell lung carcinoma.